scholarly journals Estimation of Interleukin‐10 and Interleukin‐22 Levels in the Advances of Breast Cancer

2021 ◽  
pp. 1-16
Author(s):  
Michelle Teodoro Alves ◽  
Ricardo Simões ◽  
Rodrigo Mendonça Cardoso Pestana ◽  
Angélica Navarro de Oliveira ◽  
Heloísa Helena Marques Oliveira ◽  
...  

2004 ◽  
Vol 6 (1) ◽  
pp. 8-18 ◽  
Author(s):  
K Wolk ◽  
E Witte ◽  
U Reineke ◽  
K Witte ◽  
M Friedrich ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Javier Valdés-Ferrada ◽  
Natalia Muñoz-Durango ◽  
Alejandra Pérez-Sepulveda ◽  
Sabrina Muñiz ◽  
Irenice Coronado-Arrázola ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0232174 ◽  
Author(s):  
Miao Li ◽  
Chenli Yue ◽  
Xiaoxiao Zuo ◽  
Guoquan Jin ◽  
Guanying Wang ◽  
...  

2009 ◽  
Vol 119 (3) ◽  
pp. 701-705 ◽  
Author(s):  
Armin Gerger ◽  
Wilfried Renner ◽  
Tanja Langsenlehner ◽  
Günter Hofmann ◽  
Gudrun Knechtel ◽  
...  

2011 ◽  
Vol 205 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Jian-Rong He ◽  
Li-Juan Chen ◽  
Yi Su ◽  
Yu-Ling Cen ◽  
Lu-Ying Tang ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

Metastasis to the brain is a clinical problem in patients with breast cancer (1-3). We mined published microarray data (4, 5) to discover genes associated with brain metastasis in breast cancer. We identified significant differential expression of the beta subunit of the interleukin-10 receptor, encoded by IL10RB, in the brain metastases of patients with metastatic breast cancer. Signals transduced from the interleukin-10 receptor, and its immunosuppressive and/or tolerogenic properties (6-10) may be relevant to the biology underlying colonization of the brain with metastatic breast cancer clones.


2020 ◽  
Vol 25 (6) ◽  
pp. 200-207
Author(s):  
N. V. Agranovich ◽  
Margarita S. Sivolapova ◽  
D. V. Kirsanova ◽  
A. G. Marchenko ◽  
L. A. Gulieva ◽  
...  

Background. Cellular immunity and cytotoxic agents are involved in the inflammatory process and tumor cell apoptosis resolution.Background. Cellular immunity and cytotoxic agents are involved in the inflammatory process and tumor cell apoptosis resolution. Endothelial cell apoptosis violation, imbalanced cytokines are considered as one of the contributory factors for postmastectomy lymphedema development. Aim. To assess the correlation between the interleukin profile (interleukin-10 and tumor necrosis factor-alpha) and clinical indicators of postmastectomy lymphedema in the rehabilitation treatment course after complex breast cancer treatment Materials and methods. The study involved 50 people aged 4065 years. The main group consisted of 40 females who underwent a rehabilitation treatment course for postmastectomy lymphedema. The control group consisted of 10 females with a verified breast cancer diagnosis who were preparing for surgical treatment. The statistical analysis determined the differences between the mean values of indicators using the Mann-Whitney U-test and the Wilcoxon T-test. Spearmans nonparametric correlation analysis was used to determine the relationship between the studied characteristics. Differences between indicators were considered statistically significant at p 0.05. Results. The indices of the studied interleukins in the control group are significantly higher than that of the main group. Interleukin-10 remained unchanged in the course of restorative treatment, whereas tumor necrosis factor-alpha increased from 43.72 10 pg/l to 118.94 14.74 pg/l. After the course, a statistically significant correlation (p 0.05) was found between the levels of the studied interleukins. A positive trend was observed as a result of rehabilitation treatment of postmastectomy lymphedema: the average excess volume in patients of the main group decreased by 38.5%. Conclusion. Evaluation of interleukin-10 and tumor necrosis factor-alpha in patients with postmastectomy lymphedema allows not only the restorative treatment results assessment and determination of the immune status parameter and damage degree of the vascular endothelium of a particular patient but also prognosis formation of malignant neoplasm development.


2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 204s-204s
Author(s):  
C. Liu ◽  
B. Sun ◽  
B. Xu ◽  
X. Meng ◽  
L. Li ◽  
...  

Background: Programmed cell death protein 1 (PD-1), an immune checkpoint molecule, has recently been recognized as a predictive and prognostic biomarker in several malignant tumors, but its diagnostic value remains largely unknown. Aim: We aimed to investigate the differential diagnostic efficiency of PD-1 and other immune molecules, and propose a panel of immune molecules combined with cancer antigen 15-3 (CA15-3) to distinguish breast cancer (BC) from benign breast disease (BBD). Methods: Ninety-one eligible BC patients and 31 BBD patients were enrolled. Pretreatment peripheral blood was collected and tested for mRNA expression of PD-1, cytotoxic T lymphocyte antigen 4 (CTLA-4), forkhead box P3 (FOXP3), transforming growth factor beta (TGF-β), interleukin-10 (IL-10), IL-2 receptor alpha (IL-2Rα), and cluster of differentiation 28 (CD28) by quantitative real-time PCR. Results: The diagnostic areas under curve (AUCs) of PD-1, IL-2Rα, and IL-10 for BC-BBD discrimination were 0.764, 0.758, and 0.743, respectively. The diagnostic efficiencies of these 2 parameters in distinguishing early-stage or advanced BC from BBD were consistent with a role in BC-BBD discrimination. A panel of PD-1 + IL-10 + IL-2Rα + CA15-3 showed the highest AUC (0.862), with sensitivity of 0.933 and specificity of 0.724, for BC-BBD discrimination. In addition, for early-stage BC discrimination, this panel also had the highest AUC (0.811), with a sensitivity of 0.933 and specificity of 0.614, while for advanced BC discrimination, a panel of PD-1 + IL-10 + CA15-3 exhibited the highest AUC (0.896), with a sensitivity of 0.933 and specificity of 0.783. Conclusion: These data indicate that the panel containing PD-1, IL-2Rα, IL-10, and CA15-3 can effectively discriminate BC from BBD with a high efficiency. After further confirmation, it could be used to complement conventional imaging modalities, especially in discriminating early-stage BC from BBD.


Sign in / Sign up

Export Citation Format

Share Document